The pivotal phase 3 LIBRETTO-531 clinical trial has affirmed the superiority of selpercatinib as a premier therapeutic option for individuals afflicted with RET-mutant MTC, demonstrating superior efficacy and safety over cabozantinib or vandetanib. This evidence concerns the gene RET and medullary thyroid gland carcinoma.